NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer.

Evasion from drug-induced apoptosis is a crucial mechanism of cancer treatment resistance. The proapoptotic protein NOXA marks an aggressive pancreatic ductal adenocarcinoma (PDAC) subtype. To identify drugs that unleash the death-inducing potential of NOXA, we performed an unbiased drug screening experiment.

[F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma.

Purpose: In this prospective exploratory study, we evaluated the feasibility of [F]fluorodeoxyglucose ([F]FDG) PET/MRI-based chemotherapy response prediction in pancreatic ductal adenocarcinoma at two weeks upon therapy onset.

Material And Methods: In a mixed cohort, seventeen patients treated with chemotherapy in neoadjuvant or palliative intent were enrolled. All patients were imaged by [F]FDG PET/MRI before and two weeks after onset of chemotherapy.